<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00960986</url>
  </required_header>
  <id_info>
    <org_study_id>9884</org_study_id>
    <secondary_id>F1J-MC-HMFL</secondary_id>
    <nct_id>NCT00960986</nct_id>
  </id_info>
  <brief_title>A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder</brief_title>
  <official_title>A Phase 4 Comparison of Duloxetine Dosing Strategies in the Treatment of Korean Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess nausea severity in response to four different drug
      dosing strategies of Duloxetine (30 mg with food, 60 mg with food, 30 mg without food, and 60
      mg without food) in Korean patients with major depressive disorder (MDD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Maximum Nausea Severity, Association for Methodology and Documentation in Psychiatry (AMDP-5) Adverse Event (AE) Scale Item 112 (Nausea)</measure>
    <time_frame>1 week and 8 weeks</time_frame>
    <description>AMDP-5 AE scale Item 112 (nausea) measured nausea severity during treatment (Week 0-8). The scores ranged from 0-3: 0=Not present; 1=Mild; 2=Moderate; 3=Severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 8-Week Endpoint in Association for Methodology and Documentation in Psychiatry (AMDP-5) Adverse Event (AE) Scale Item 112 (Nausea)</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Scores for AE scale Item 112 (nausea) of AMDP-5 (Week 0-8) ranged from 0-3: 0=Not present; 1=Mild; 2=Moderate; 3=Severe. Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 1-Week and 8-Week Endpoints in Association for Methodology and Documentation in Psychiatry (AMDP-5) Measure: Gastric Events Score</measure>
    <time_frame>Baseline, 1 week and 8 weeks</time_frame>
    <description>Gastric events scores (average of Item 112 [nausea] + Item 113 [vomiting]) of AMDP-5 (Week 0-8) ranged from 0-3: 0=Not present; 1=Mild; 2=Moderate; 3=Severe. Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 1-Week and 8-Week Endpoints in Association for Methodology and Documentation in Psychiatry (AMDP-5) Measure: Common Adverse Events (AEs) Score</measure>
    <time_frame>Baseline, 1 week, 8 weeks</time_frame>
    <description>AMDP-5 common AEs score was used to create a composite measure of AEs from previous duloxetine studies (incidence &gt;5% and 2X placebo rate). The common AEs total score was the sum of the following 8 AMDP-5 items: 1) Mean of Item 112 (nausea) + 113 (vomiting); 2) Item 111 (dry mouth); 3) Item 115 (constipation); 4) Mean of Items 101-104 (insomnia); Item 122 (increased perspiration); 8) Item 106 (decreased appetite). Score was based on a 5-point scale: 1=absent, 2=mild, 3=moderate, 4=severe, 5=extremely severe; Higher score=worse severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score</measure>
    <time_frame>Baseline, 1 week, 8 weeks</time_frame>
    <description>The HAMD-17 total score ranged from 0 (not at all depressed)-52 (severely depressed). Least squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariance matrix.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Maier Subscale</measure>
    <time_frame>Baseline, 1 week, 8 weeks</time_frame>
    <description>The HAMD-17 Maier subscale (Items 1, 2, 7, 8, 9, 10 of HAMD-17 questionnaire) represented the &quot;core&quot; symptoms of depression. Total subscale scores ranged from 0 (normal)-24 (severe). Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Core Mood Subscale</measure>
    <time_frame>Baseline, 1 week, 8 weeks</time_frame>
    <description>The HAMD-17 Core Mood subscale (Items 1, 2, 3, 7, 8 of HAMD-17 questionnaire) represented the core symptoms of depression. Total subscale scores ranged from 0 (normal)-20 (severe). Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Anxiety/Somatization Subscale</measure>
    <time_frame>Baseline, 1 week, 8 weeks</time_frame>
    <description>The HAMD-17 Anxiety/Somatization subscale (Items 10, 11, 12, 13, 15, 17 of HAMD-17 questionnaire) evaluated the severity of psychic and somatic manifestations of anxiety and agitation. Total subscale scores ranged from 0 (normal)-18 (severe). Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Retardation/Somatization Subscale</measure>
    <time_frame>Baseline, 1 week, 8 weeks</time_frame>
    <description>The HAMD-17 Retardation/Somatization subscale (Items 1, 7, 8, 14 of HAMD-17 questionnaire) evaluated dysfunction in mood, work, sexual activity, and overall motor retardation. Total subscale scores ranged from 0 (normal)-14 (severe). Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Sleep Subscale</measure>
    <time_frame>Baseline, 1 week, 8 weeks</time_frame>
    <description>The HAMD-17 Sleep subscale (Items 4, 5, 6 of HAMD-17 questionnaire) evaluated initial, middle, and late insomnia. Total subscale scores ranged from 0 (no difficulty)-6 (difficulty). Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 1-Week and 8-Week Endpoints in Clinical Global Impressions of Severity (CGI-S)</measure>
    <time_frame>Baseline, 1 week, 8 weeks</time_frame>
    <description>The CGI-S Rating Scale was a 7-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; or 7=extremely ill. Least squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariance matrix.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I) at 1 Week and 8 Weeks</measure>
    <time_frame>1 week, 8 weeks</time_frame>
    <description>The PGI-I Rating Scale was a 7-point scale: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Least squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction and an unstructured covariance matrix.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Nausea</measure>
    <time_frame>Baseline to onset of nausea (Baseline up to 8 weeks)</time_frame>
    <description>Events of nausea were taken from the adverse event (AE) data. Participants were censored based on the following rules: 1=study discontinuation date if the participant discontinues the study; 2=study lost to follow-up date if the participant drops out of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolve Nausea</measure>
    <time_frame>Nausea onset up to nausea resolve (Baseline up to 8 weeks)</time_frame>
    <description>Events of nausea were taken from the adverse event (AE) data. Participants were censored based on the following rules: 1=study discontinuation date if the participant discontinues the study; 2=study lost to follow-up date if the participant drops out of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Response</measure>
    <time_frame>Baseline up to 8 weeks</time_frame>
    <description>Response was defined as ≥50% decrease from baseline on the 17-item Hamilton Depression Rating Scale (HAMD-17) total score. HAMD-17 total scores ranged from 0 (not at all depressed)-52 (severely depressed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Remission</measure>
    <time_frame>Baseline up to 8 weeks</time_frame>
    <description>Remission was defined as 17-item Hamilton Depression Rating Scale (HAMD-17) total score ≤7. HAMD-17 total scores ranged from 0 (not at all depressed)-52 (severely depressed).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">249</enrollment>
  <condition>Major Depressive Disorder (MDD)</condition>
  <arm_group>
    <arm_group_label>Duloxetine 60 mg with food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duloxetine 60 mg without food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duloxetine 30 mg with food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duloxetine 30 mg without food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine hydrochloride</intervention_name>
    <description>po, QD</description>
    <arm_group_label>Duloxetine 60 mg with food</arm_group_label>
    <arm_group_label>Duloxetine 60 mg without food</arm_group_label>
    <arm_group_label>Duloxetine 30 mg with food</arm_group_label>
    <arm_group_label>Duloxetine 30 mg without food</arm_group_label>
    <other_name>Cymbalta</other_name>
    <other_name>LY248686</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For females of child-bearing potential test negative for pregnancy at the time of
             enrollment based on a urine pregnancy test and agree to use a reliable method of birth
             control during the study and for 1 month following the last dose of study drug.

          -  17-item Hamilton Depression Rating Scale (HAMD-17) total score &gt;15 at Screening and
             Randomization

          -  Have signed the informed consent document (ICD)

          -  Have a level of understanding sufficient to provide informed consent and to
             communicate with the investigators and site personnel

          -  Are judged to be reliable and agree to keep all appointments for clinic visits, tests,
             and procedures required by the protocol

          -  Patients must meet Diagnostic and Statistical Manual of Mental Disorders-fourth
             edition-text revision (DSM-IV-TR) criteria for Major Depressive Disorder (MDD). The
             Mini International Neuropsychiatric Interview (MINI) will be used to establish the
             diagnosis and exclude other psychiatric illnesses.

        Exclusion Criteria:

          -  Treatment within the last 30 days with a drug that has not received regulatory
             approval for any indication at the time of study entry

          -  Have any current primary Axis I disorder other than MDD

          -  Have any previous diagnosis of bipolar disorder, schizophrenia, or other psychotic
             disorders

          -  Lack of response of the current episode of major depression to two or more adequate
             courses of antidepressant therapy at clinically appropriate dose for a minimum of 4
             weeks or, in the judgment of the investigator, the patient meets criteria for
             treatment-resistant depression

          -  Have a history of a lack of response, at any time, to an adequate trial of duloxetine
             (defined as treatment with at least 60 mg/day of duloxetine for a minimum of 4 weeks)

          -  Presence of an Axis II disorder that, in the judgment of the investigator, would
             interfere with study compliance

          -  DSM-IV-TR-defined history of substance abuse or dependence within the past 6 months,
             excluding nicotine and caffeine

          -  Patients judged to be at serious suicidal risk in the opinion of the investigator
             and/or score ≥3 on Item 3 (suicide) of the HAMD-17

          -  Serious medical illness or clinically significant laboratory abnormalities that, in
             the judgment of the investigator, are likely to require
             intervention/hospitalization/excluded medication during the course of the study Note:
             Patients with acute liver injury (such as hepatitis) or severe (Child-Pugh Class C)
             cirrhosis will be excluded

          -  Have an acute or chronic medical illness with the main symptoms of nausea or
             gastrointestinal discomfort or taking any medication known to have major gastric
             effects that would interfere with nausea ratings.

          -  Electroconvulsive therapy (ECT) or Transcranial Magnetic Stimulation (TMS) within the
             past year

          -  Taking any excluded medications within 7 days prior to Randomization.

          -  Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days prior to
             Randomization or potential need to use a MAOI within 5 days after discontinuation of
             study drug.

          -  Treatment with fluoxetine within 30 days prior to Randomization.

          -  Frequent and/or severe allergic reactions with multiple medications or known
             hypersensitivity to duloxetine.

          -  Abnormal thyroid stimulating hormone (TSH) concentration. Note: Participants diagnosed
             with hyperthyroidism or hypothyroidism who were treated with a stable dose of thyroid
             supplement for at least the past 3 months, have medically appropriate TSH
             concentration, and are clinically euthyroid, are allowed to enroll in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5PM Eastern time (UTC/GMT - 5hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cheong Ju-City</city>
        <zip>361-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Goyang-Si</city>
        <zip>410-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seongnam-Si</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>134-791</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sungnam-Si</city>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Suwon-City</city>
        <zip>442-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yangsan</city>
        <zip>626-770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <results_first_submitted>January 17, 2012</results_first_submitted>
  <results_first_submitted_qc>March 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 17, 2012</results_first_posted>
  <last_update_submitted>December 8, 2014</last_update_submitted>
  <last_update_submitted_qc>December 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Period 1 was a 3- to 30-day screening and washout period; Period 2 (Week 0-1) was a 1-week initial dosing period (randomization to duloxetine 30 mg with food, 30 mg without food, 60 mg with food, or 60 mg without food); Period 3 (Week 1-8) was a 7-week therapy period (treatment switched to duloxetine 60 mg once daily (QD) until study end.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Duloxetine 60 mg With Food</title>
          <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Duloxetine 60 mg Without Food</title>
          <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>Duloxetine 30 mg With Food</title>
          <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
        </group>
        <group group_id="P4">
          <title>Duloxetine 30 mg Without Food</title>
          <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (Screening and Washout)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 (1-week Initial Dosing Period)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3 (7-week Therapy Period)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Duloxetine 60 mg With Food</title>
          <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Duloxetine 60 mg Without Food</title>
          <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Duloxetine 30 mg With Food</title>
          <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
        </group>
        <group group_id="B4">
          <title>Duloxetine 30 mg Without Food</title>
          <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="63"/>
            <count group_id="B4" value="64"/>
            <count group_id="B5" value="249"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.65" lower_limit="31.58" upper_limit="53.73"/>
                    <measurement group_id="B2" value="47.90" lower_limit="38.65" upper_limit="58.90"/>
                    <measurement group_id="B3" value="49.94" lower_limit="40.04" upper_limit="62.24"/>
                    <measurement group_id="B4" value="44.65" lower_limit="32.84" upper_limit="56.92"/>
                    <measurement group_id="B5" value="46.81" lower_limit="34.78" upper_limit="59.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI measures the participant's body weight divided by the square of his or her height.</description>
          <units>kilogram per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.56" spread="4.034"/>
                    <measurement group_id="B2" value="23.28" spread="3.133"/>
                    <measurement group_id="B3" value="23.06" spread="3.430"/>
                    <measurement group_id="B4" value="23.84" spread="3.612"/>
                    <measurement group_id="B5" value="23.67" spread="3.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previously diagnosed with major depressive disorder (MDD)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration since first major depressive disorder (MDD) episode</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.47" lower_limit="0.52" upper_limit="4.29"/>
                    <measurement group_id="B2" value="2.65" lower_limit="0.77" upper_limit="5.32"/>
                    <measurement group_id="B3" value="2.52" lower_limit="0.48" upper_limit="9.12"/>
                    <measurement group_id="B4" value="1.29" lower_limit="0.52" upper_limit="4.40"/>
                    <measurement group_id="B5" value="1.92" lower_limit="0.54" upper_limit="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at first major depressive disorder (MDD) episode</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.21" lower_limit="29.00" upper_limit="51.00"/>
                    <measurement group_id="B2" value="43.33" lower_limit="34.67" upper_limit="53.00"/>
                    <measurement group_id="B3" value="43.86" lower_limit="27.00" upper_limit="59.60"/>
                    <measurement group_id="B4" value="41.58" lower_limit="29.00" upper_limit="54.00"/>
                    <measurement group_id="B5" value="42.52" lower_limit="30.00" upper_limit="54.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of previous MDD episodes/exacerbations in the last 24 months</title>
          <units>number of episodes in last 24 months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0" lower_limit="0.0" upper_limit="1.0"/>
                    <measurement group_id="B2" value="1.0" lower_limit="0.0" upper_limit="1.0"/>
                    <measurement group_id="B3" value="1.0" lower_limit="0.0" upper_limit="1.0"/>
                    <measurement group_id="B4" value="1.0" lower_limit="0.0" upper_limit="1.0"/>
                    <measurement group_id="B5" value="1.0" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Received previous therapy for current episode</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>17-item Hamilton Depression Rating Scale (HAMD-17) Total Score</title>
          <description>The HAMD-17 measured depression severity. Each item was evaluated and scored using either a 5-point scale (for example, absent; mild; moderate; severe; very severe) or a 3-point scale (for example, absent; mild; marked). The total score ranged from 0 (not at all depressed)-52 (severely depressed).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.0" spread="5.18"/>
                    <measurement group_id="B2" value="22.3" spread="5.69"/>
                    <measurement group_id="B3" value="22.9" spread="5.45"/>
                    <measurement group_id="B4" value="20.3" spread="5.23"/>
                    <measurement group_id="B5" value="21.6" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impression of Severity (CGI-S) Score</title>
          <description>The CGI-S Rating Scale was a 7-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; or 7=extremely ill.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.4" lower_limit="4.0" upper_limit="5.0"/>
                    <measurement group_id="B2" value="4.5" lower_limit="4.0" upper_limit="5.0"/>
                    <measurement group_id="B3" value="4.7" lower_limit="4.0" upper_limit="5.0"/>
                    <measurement group_id="B4" value="4.2" lower_limit="4.0" upper_limit="5.0"/>
                    <measurement group_id="B5" value="4.4" lower_limit="4.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Association for Methodology and Documentation in Psychiatry (AMDP-5) Item 112 (Nausea) Score</title>
          <description>AMDP-5 Item 112 (nausea) measured nausea severity. The scores ranged from 0-3: 0=Not present; 1=Mild; 2=Moderate; 3=Severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.3" spread="0.72" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="B2" value="0.2" spread="0.59" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="B3" value="0.2" spread="0.61" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="B4" value="0.1" spread="0.38" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="B5" value="0.2" spread="0.58" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Maximum Nausea Severity, Association for Methodology and Documentation in Psychiatry (AMDP-5) Adverse Event (AE) Scale Item 112 (Nausea)</title>
        <description>AMDP-5 AE scale Item 112 (nausea) measured nausea severity during treatment (Week 0-8). The scores ranged from 0-3: 0=Not present; 1=Mild; 2=Moderate; 3=Severe.</description>
        <time_frame>1 week and 8 weeks</time_frame>
        <population>The safety population included all participants who took at least 1 study drug dose analysed according to the drug dose actually taken.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg With Food</title>
            <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Without Food</title>
            <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 30 mg With Food</title>
            <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 30 mg Without Food</title>
            <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Maximum Nausea Severity, Association for Methodology and Documentation in Psychiatry (AMDP-5) Adverse Event (AE) Scale Item 112 (Nausea)</title>
          <description>AMDP-5 AE scale Item 112 (nausea) measured nausea severity during treatment (Week 0-8). The scores ranged from 0-3: 0=Not present; 1=Mild; 2=Moderate; 3=Severe.</description>
          <population>The safety population included all participants who took at least 1 study drug dose analysed according to the drug dose actually taken.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.06" upper_limit="1.69"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.89" upper_limit="1.49"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.62" upper_limit="1.11"/>
                    <measurement group_id="O4" value="0.8" lower_limit="0.57" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-8 (n=35; n=43; n=48; n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.25" upper_limit="0.67"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.27" upper_limit="0.66"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.45" upper_limit="0.96"/>
                    <measurement group_id="O4" value="0.4" lower_limit="0.19" upper_limit="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 8-Week Endpoint in Association for Methodology and Documentation in Psychiatry (AMDP-5) Adverse Event (AE) Scale Item 112 (Nausea)</title>
        <description>Scores for AE scale Item 112 (nausea) of AMDP-5 (Week 0-8) ranged from 0-3: 0=Not present; 1=Mild; 2=Moderate; 3=Severe. Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>The safety population included all participants who took at least 1 study drug dose analysed according to the drug dose actually taken. N = number of subjects with a baseline and post-baseline result at the Week 8 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg With Food</title>
            <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Without Food</title>
            <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 30 mg With Food</title>
            <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 30 mg Without Food</title>
            <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 8-Week Endpoint in Association for Methodology and Documentation in Psychiatry (AMDP-5) Adverse Event (AE) Scale Item 112 (Nausea)</title>
          <description>Scores for AE scale Item 112 (nausea) of AMDP-5 (Week 0-8) ranged from 0-3: 0=Not present; 1=Mild; 2=Moderate; 3=Severe. Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
          <population>The safety population included all participants who took at least 1 study drug dose analysed according to the drug dose actually taken. N = number of subjects with a baseline and post-baseline result at the Week 8 visit.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.08"/>
                    <measurement group_id="O2" value="-0.02" spread="0.07"/>
                    <measurement group_id="O3" value="-0.01" spread="0.07"/>
                    <measurement group_id="O4" value="-1.12" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in Association for Methodology and Documentation in Psychiatry (AMDP-5) Measure: Gastric Events Score</title>
        <description>Gastric events scores (average of Item 112 [nausea] + Item 113 [vomiting]) of AMDP-5 (Week 0-8) ranged from 0-3: 0=Not present; 1=Mild; 2=Moderate; 3=Severe. Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
        <time_frame>Baseline, 1 week and 8 weeks</time_frame>
        <population>The safety population included all participants who took at least 1 study drug dose analysed according to the drug dose actually taken.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg With Food</title>
            <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Without Food</title>
            <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 30 mg With Food</title>
            <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 30 mg Without Food</title>
            <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in Association for Methodology and Documentation in Psychiatry (AMDP-5) Measure: Gastric Events Score</title>
          <description>Gastric events scores (average of Item 112 [nausea] + Item 113 [vomiting]) of AMDP-5 (Week 0-8) ranged from 0-3: 0=Not present; 1=Mild; 2=Moderate; 3=Severe. Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
          <population>The safety population included all participants who took at least 1 study drug dose analysed according to the drug dose actually taken.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-week change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.10"/>
                    <measurement group_id="O2" value="0.72" spread="0.10"/>
                    <measurement group_id="O3" value="0.35" spread="0.10"/>
                    <measurement group_id="O4" value="0.37" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-week change (n=28; n=37; n=39; n=37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.04"/>
                    <measurement group_id="O2" value="-0.04" spread="0.04"/>
                    <measurement group_id="O3" value="-0.04" spread="0.04"/>
                    <measurement group_id="O4" value="-0.09" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in Association for Methodology and Documentation in Psychiatry (AMDP-5) Measure: Common Adverse Events (AEs) Score</title>
        <description>AMDP-5 common AEs score was used to create a composite measure of AEs from previous duloxetine studies (incidence &gt;5% and 2X placebo rate). The common AEs total score was the sum of the following 8 AMDP-5 items: 1) Mean of Item 112 (nausea) + 113 (vomiting); 2) Item 111 (dry mouth); 3) Item 115 (constipation); 4) Mean of Items 101-104 (insomnia); Item 122 (increased perspiration); 8) Item 106 (decreased appetite). Score was based on a 5-point scale: 1=absent, 2=mild, 3=moderate, 4=severe, 5=extremely severe; Higher score=worse severity.</description>
        <time_frame>Baseline, 1 week, 8 weeks</time_frame>
        <population>The safety population included all participants who took at least 1 study drug dose analysed according to the drug dose actually taken.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg With Food</title>
            <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Without Food</title>
            <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 30 mg With Food</title>
            <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 30 mg Without Food</title>
            <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in Association for Methodology and Documentation in Psychiatry (AMDP-5) Measure: Common Adverse Events (AEs) Score</title>
          <description>AMDP-5 common AEs score was used to create a composite measure of AEs from previous duloxetine studies (incidence &gt;5% and 2X placebo rate). The common AEs total score was the sum of the following 8 AMDP-5 items: 1) Mean of Item 112 (nausea) + 113 (vomiting); 2) Item 111 (dry mouth); 3) Item 115 (constipation); 4) Mean of Items 101-104 (insomnia); Item 122 (increased perspiration); 8) Item 106 (decreased appetite). Score was based on a 5-point scale: 1=absent, 2=mild, 3=moderate, 4=severe, 5=extremely severe; Higher score=worse severity.</description>
          <population>The safety population included all participants who took at least 1 study drug dose analysed according to the drug dose actually taken.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-week change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.44"/>
                    <measurement group_id="O2" value="1.28" spread="0.42"/>
                    <measurement group_id="O3" value="-0.00" spread="0.43"/>
                    <measurement group_id="O4" value="-0.37" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-week change (n=28; n=37; n=39; n=37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.54" spread="0.47"/>
                    <measurement group_id="O2" value="-2.99" spread="0.42"/>
                    <measurement group_id="O3" value="-2.33" spread="0.41"/>
                    <measurement group_id="O4" value="-3.23" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score</title>
        <description>The HAMD-17 total score ranged from 0 (not at all depressed)-52 (severely depressed). Least squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariance matrix.</description>
        <time_frame>Baseline, 1 week, 8 weeks</time_frame>
        <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg With Food</title>
            <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Without Food</title>
            <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 30 mg With Food</title>
            <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 30 mg Without Food</title>
            <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score</title>
          <description>The HAMD-17 total score ranged from 0 (not at all depressed)-52 (severely depressed). Least squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariance matrix.</description>
          <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-week change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.83" spread="0.57"/>
                    <measurement group_id="O2" value="-2.85" spread="0.55"/>
                    <measurement group_id="O3" value="-3.84" spread="0.56"/>
                    <measurement group_id="O4" value="-4.34" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-week change (n=28; n=37; n=39; n=37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.39" spread="1.01"/>
                    <measurement group_id="O2" value="-13.45" spread="0.90"/>
                    <measurement group_id="O3" value="-13.60" spread="0.88"/>
                    <measurement group_id="O4" value="-13.07" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Maier Subscale</title>
        <description>The HAMD-17 Maier subscale (Items 1, 2, 7, 8, 9, 10 of HAMD-17 questionnaire) represented the &quot;core&quot; symptoms of depression. Total subscale scores ranged from 0 (normal)-24 (severe). Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
        <time_frame>Baseline, 1 week, 8 weeks</time_frame>
        <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg With Food</title>
            <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Without Food</title>
            <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 30 mg With Food</title>
            <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 30 mg Without Food</title>
            <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Maier Subscale</title>
          <description>The HAMD-17 Maier subscale (Items 1, 2, 7, 8, 9, 10 of HAMD-17 questionnaire) represented the &quot;core&quot; symptoms of depression. Total subscale scores ranged from 0 (normal)-24 (severe). Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
          <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-week change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="0.33"/>
                    <measurement group_id="O2" value="-1.90" spread="0.32"/>
                    <measurement group_id="O3" value="-2.15" spread="0.32"/>
                    <measurement group_id="O4" value="-2.64" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-week change (n=28; n=37; n=39; n=37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.01" spread="0.50"/>
                    <measurement group_id="O2" value="-7.12" spread="0.45"/>
                    <measurement group_id="O3" value="-7.55" spread="0.44"/>
                    <measurement group_id="O4" value="-7.30" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Core Mood Subscale</title>
        <description>The HAMD-17 Core Mood subscale (Items 1, 2, 3, 7, 8 of HAMD-17 questionnaire) represented the core symptoms of depression. Total subscale scores ranged from 0 (normal)-20 (severe). Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
        <time_frame>Baseline, 1 week, 8 weeks</time_frame>
        <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg With Food</title>
            <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Without Food</title>
            <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 30 mg With Food</title>
            <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 30 mg Without Food</title>
            <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Core Mood Subscale</title>
          <description>The HAMD-17 Core Mood subscale (Items 1, 2, 3, 7, 8 of HAMD-17 questionnaire) represented the core symptoms of depression. Total subscale scores ranged from 0 (normal)-20 (severe). Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
          <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-week change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" spread="0.27"/>
                    <measurement group_id="O2" value="-1.18" spread="0.26"/>
                    <measurement group_id="O3" value="-1.52" spread="0.26"/>
                    <measurement group_id="O4" value="-1.76" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-week change (n=28; n=37; n=39; n=37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.18" spread="0.40"/>
                    <measurement group_id="O2" value="-5.39" spread="0.36"/>
                    <measurement group_id="O3" value="-5.85" spread="0.35"/>
                    <measurement group_id="O4" value="-5.67" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Anxiety/Somatization Subscale</title>
        <description>The HAMD-17 Anxiety/Somatization subscale (Items 10, 11, 12, 13, 15, 17 of HAMD-17 questionnaire) evaluated the severity of psychic and somatic manifestations of anxiety and agitation. Total subscale scores ranged from 0 (normal)-18 (severe). Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
        <time_frame>Baseline, 1 week, 8 weeks</time_frame>
        <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg With Food</title>
            <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Without Food</title>
            <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 30 mg With Food</title>
            <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 30 mg Without Food</title>
            <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Anxiety/Somatization Subscale</title>
          <description>The HAMD-17 Anxiety/Somatization subscale (Items 10, 11, 12, 13, 15, 17 of HAMD-17 questionnaire) evaluated the severity of psychic and somatic manifestations of anxiety and agitation. Total subscale scores ranged from 0 (normal)-18 (severe). Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
          <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-week change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.25"/>
                    <measurement group_id="O2" value="-1.15" spread="0.24"/>
                    <measurement group_id="O3" value="-1.36" spread="0.24"/>
                    <measurement group_id="O4" value="-1.41" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-week change (n=28; n=37; n=39; n=37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.93" spread="0.41"/>
                    <measurement group_id="O2" value="-4.50" spread="0.36"/>
                    <measurement group_id="O3" value="-4.57" spread="0.35"/>
                    <measurement group_id="O4" value="-4.26" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Retardation/Somatization Subscale</title>
        <description>The HAMD-17 Retardation/Somatization subscale (Items 1, 7, 8, 14 of HAMD-17 questionnaire) evaluated dysfunction in mood, work, sexual activity, and overall motor retardation. Total subscale scores ranged from 0 (normal)-14 (severe). Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
        <time_frame>Baseline, 1 week, 8 weeks</time_frame>
        <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg With Food</title>
            <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Without Food</title>
            <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 30 mg With Food</title>
            <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 30 mg Without Food</title>
            <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Retardation/Somatization Subscale</title>
          <description>The HAMD-17 Retardation/Somatization subscale (Items 1, 7, 8, 14 of HAMD-17 questionnaire) evaluated dysfunction in mood, work, sexual activity, and overall motor retardation. Total subscale scores ranged from 0 (normal)-14 (severe). Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
          <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-week change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.22"/>
                    <measurement group_id="O2" value="-0.87" spread="0.21"/>
                    <measurement group_id="O3" value="-1.02" spread="0.22"/>
                    <measurement group_id="O4" value="-1.20" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-week change (n=28; n=37; n=39; n=37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.92" spread="0.35"/>
                    <measurement group_id="O2" value="-4.37" spread="0.31"/>
                    <measurement group_id="O3" value="-4.63" spread="0.31"/>
                    <measurement group_id="O4" value="-4.55" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Sleep Subscale</title>
        <description>The HAMD-17 Sleep subscale (Items 4, 5, 6 of HAMD-17 questionnaire) evaluated initial, middle, and late insomnia. Total subscale scores ranged from 0 (no difficulty)-6 (difficulty). Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
        <time_frame>Baseline, 1 week, 8 weeks</time_frame>
        <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg With Food</title>
            <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Without Food</title>
            <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 30 mg With Food</title>
            <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 30 mg Without Food</title>
            <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Sleep Subscale</title>
          <description>The HAMD-17 Sleep subscale (Items 4, 5, 6 of HAMD-17 questionnaire) evaluated initial, middle, and late insomnia. Total subscale scores ranged from 0 (no difficulty)-6 (difficulty). Least Squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariate matrix.</description>
          <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-week change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.21"/>
                    <measurement group_id="O2" value="-0.64" spread="0.21"/>
                    <measurement group_id="O3" value="-0.66" spread="0.21"/>
                    <measurement group_id="O4" value="-1.01" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-week change (n=28; n=37; n=39; n=37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.77" spread="0.27"/>
                    <measurement group_id="O2" value="-2.32" spread="0.24"/>
                    <measurement group_id="O3" value="-2.09" spread="0.23"/>
                    <measurement group_id="O4" value="-2.10" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in Clinical Global Impressions of Severity (CGI-S)</title>
        <description>The CGI-S Rating Scale was a 7-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; or 7=extremely ill. Least squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariance matrix.</description>
        <time_frame>Baseline, 1 week, 8 weeks</time_frame>
        <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg With Food</title>
            <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Without Food</title>
            <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 30 mg With Food</title>
            <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 30 mg Without Food</title>
            <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 1-Week and 8-Week Endpoints in Clinical Global Impressions of Severity (CGI-S)</title>
          <description>The CGI-S Rating Scale was a 7-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; or 7=extremely ill. Least squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction, and an unstructured covariance matrix.</description>
          <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-week change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.09"/>
                    <measurement group_id="O2" value="-0.36" spread="0.09"/>
                    <measurement group_id="O3" value="-0.44" spread="0.09"/>
                    <measurement group_id="O4" value="-0.63" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-week change (n=28; n=37; n=39; n=37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.43" spread="0.17"/>
                    <measurement group_id="O2" value="-2.13" spread="0.15"/>
                    <measurement group_id="O3" value="-2.23" spread="0.15"/>
                    <measurement group_id="O4" value="-2.27" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Improvement (PGI-I) at 1 Week and 8 Weeks</title>
        <description>The PGI-I Rating Scale was a 7-point scale: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Least squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction and an unstructured covariance matrix.</description>
        <time_frame>1 week, 8 weeks</time_frame>
        <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg With Food</title>
            <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Without Food</title>
            <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 30 mg With Food</title>
            <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 30 mg Without Food</title>
            <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Improvement (PGI-I) at 1 Week and 8 Weeks</title>
          <description>The PGI-I Rating Scale was a 7-point scale: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Least squares (LS) Means were adjusted for treatment group, site, visit and treatment-by-visit interaction, gender, age, baseline score and baseline score-by-visit interaction and an unstructured covariance matrix.</description>
          <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-week change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72" spread="0.13"/>
                    <measurement group_id="O2" value="3.77" spread="0.13"/>
                    <measurement group_id="O3" value="3.52" spread="0.13"/>
                    <measurement group_id="O4" value="3.47" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-week change (n=28; n=37; n=39; n=37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="0.19"/>
                    <measurement group_id="O2" value="2.40" spread="0.17"/>
                    <measurement group_id="O3" value="2.36" spread="0.16"/>
                    <measurement group_id="O4" value="2.40" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Nausea</title>
        <description>Events of nausea were taken from the adverse event (AE) data. Participants were censored based on the following rules: 1=study discontinuation date if the participant discontinues the study; 2=study lost to follow-up date if the participant drops out of the study.</description>
        <time_frame>Baseline to onset of nausea (Baseline up to 8 weeks)</time_frame>
        <population>The safety population included all participants who took at least 1 study drug dose analysed according to the drug dose actually taken.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg With Food</title>
            <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Without Food</title>
            <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 30 mg With Food</title>
            <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 30 mg Without Food</title>
            <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Nausea</title>
          <description>Events of nausea were taken from the adverse event (AE) data. Participants were censored based on the following rules: 1=study discontinuation date if the participant discontinues the study; 2=study lost to follow-up date if the participant drops out of the study.</description>
          <population>The safety population included all participants who took at least 1 study drug dose analysed according to the drug dose actually taken.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="9.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0">The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment.</measurement>
                    <measurement group_id="O3" value="7.0" lower_limit="2.0" upper_limit="56.0"/>
                    <measurement group_id="O4" value="6.0" lower_limit="1.0">The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolve Nausea</title>
        <description>Events of nausea were taken from the adverse event (AE) data. Participants were censored based on the following rules: 1=study discontinuation date if the participant discontinues the study; 2=study lost to follow-up date if the participant drops out of the study.</description>
        <time_frame>Nausea onset up to nausea resolve (Baseline up to 8 weeks)</time_frame>
        <population>The safety population included all participants who took at least 1 study drug dose analysed according to the drug dose actually taken.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg With Food</title>
            <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Without Food</title>
            <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 30 mg With Food</title>
            <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 30 mg Without Food</title>
            <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolve Nausea</title>
          <description>Events of nausea were taken from the adverse event (AE) data. Participants were censored based on the following rules: 1=study discontinuation date if the participant discontinues the study; 2=study lost to follow-up date if the participant drops out of the study.</description>
          <population>The safety population included all participants who took at least 1 study drug dose analysed according to the drug dose actually taken.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="4.0" upper_limit="9.0"/>
                    <measurement group_id="O2" value="8.0" lower_limit="5.0" upper_limit="15.0"/>
                    <measurement group_id="O3" value="15.0" lower_limit="9.0" upper_limit="22.0"/>
                    <measurement group_id="O4" value="6.0" lower_limit="4.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Response</title>
        <description>Response was defined as ≥50% decrease from baseline on the 17-item Hamilton Depression Rating Scale (HAMD-17) total score. HAMD-17 total scores ranged from 0 (not at all depressed)-52 (severely depressed).</description>
        <time_frame>Baseline up to 8 weeks</time_frame>
        <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg With Food</title>
            <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Without Food</title>
            <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 30 mg With Food</title>
            <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 30 mg Without Food</title>
            <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Response</title>
          <description>Response was defined as ≥50% decrease from baseline on the 17-item Hamilton Depression Rating Scale (HAMD-17) total score. HAMD-17 total scores ranged from 0 (not at all depressed)-52 (severely depressed).</description>
          <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8"/>
                    <measurement group_id="O2" value="49.2"/>
                    <measurement group_id="O3" value="47.5"/>
                    <measurement group_id="O4" value="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Remission</title>
        <description>Remission was defined as 17-item Hamilton Depression Rating Scale (HAMD-17) total score ≤7. HAMD-17 total scores ranged from 0 (not at all depressed)-52 (severely depressed).</description>
        <time_frame>Baseline up to 8 weeks</time_frame>
        <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg With Food</title>
            <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Without Food</title>
            <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 30 mg With Food</title>
            <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 30 mg Without Food</title>
            <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Remission</title>
          <description>Remission was defined as 17-item Hamilton Depression Rating Scale (HAMD-17) total score ≤7. HAMD-17 total scores ranged from 0 (not at all depressed)-52 (severely depressed).</description>
          <population>The efficacy population included the number of participants with baseline and at least 1 post-baseline value analysed under the intent-to-treat (ITT) principle according to the drug dose they were assigned.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="37.3"/>
                    <measurement group_id="O3" value="35.6"/>
                    <measurement group_id="O4" value="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Duloxetine 30 mg With Food</title>
          <description>Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks</description>
        </group>
        <group group_id="E2">
          <title>Duloxetine 60 mg With Food</title>
          <description>Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>Duloxetine 30 mg Without Food</title>
          <description>Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks</description>
        </group>
        <group group_id="E4">
          <title>Duloxetine 60 mg Without Food</title>
          <description>Duloxetine 60 mg capsule po QD without food for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="63"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="59"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="63"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="59"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="42" subjects_affected="39" subjects_at_risk="63"/>
                <counts group_id="E2" events="49" subjects_affected="41" subjects_at_risk="59"/>
                <counts group_id="E3" events="43" subjects_affected="38" subjects_at_risk="64"/>
                <counts group_id="E4" events="43" subjects_affected="39" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="63"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="59"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="63"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="63"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="59"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="64"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Large number of protocol violations; bias due to unblinded, open-label design (participants were predisposed to expect an outcome of nausea as the primary endpoint); use of emetogenic medications; incorrect reporting and intake of food and drug.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

